JSPR (Jasper Therapeutics) Other Long-Term Liabilities: $2.54 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JSPR Jasper Therapeutics Inc JSPR
30 GF Score
Price $0.71
! 1 Warning Sign
View Full Analysis

What is Jasper Therapeutics Other Long-Term Liabilities?

Jasper Therapeutics JSPR +4.53% 30 Other Long-Term Liabilities is $2.54 Mil as of Jun. 2026. GuruFocus rates JSPR with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Jasper Therapeutics's other long-term liabilities for the quarter that ended in Jun. 2026 was $2.54 Mil.

Jasper Therapeutics's quarterly other long-term liabilities declined from Dec. 2025 ($18.43 Mil) to Mar. 2026 ($8.79 Mil) and declined from Mar. 2026 ($8.79 Mil) to Jun. 2026 ($2.54 Mil).

Jasper Therapeutics's annual other long-term liabilities stayed the same from Dec. 2023 ($2.26 Mil) to Dec. 2024 ($2.26 Mil) but then increased from Dec. 2024 ($2.26 Mil) to Dec. 2025 ($18.43 Mil).

Jasper Therapeutics Other Long-Term Liabilities Related Terms

Jasper Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Jasper Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jasper Therapeutics Other Long-Term Liabilities Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial 13.69 2.51 2.26 2.26 18.43

Jasper Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.26 24.86 18.43 8.79 2.54
JSPR
30GF Score
Jasper Therapeutics Inc JSPR
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jasper Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $2.54 Mil mean?
Jasper Therapeutics (JSPR) has a Other Long-Term Liabilities of $2.54 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Jasper Therapeutics and its competitors.
Is Jasper Therapeutics' Other Long-Term Liabilities too high?
Jasper Therapeutics' current Other Long-Term Liabilities is $2.54 Mil. Overall, Jasper Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Jasper Therapeutics' Other Long-Term Liabilities compare to CNSY and MRKR?
Jasper Therapeutics' Other Long-Term Liabilities of $2.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Jasper Therapeutics and its competitors. Jasper Therapeutics's current Other Long-Term Liabilities is $2.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jasper Therapeutics stock overvalued right now?
Jasper Therapeutics (JSPR) has a current Other Long-Term Liabilities of $2.54 Mil. The current Other Long-Term Liabilities is $2.54 Mil. Jasper Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Jasper Therapeutics (JSPR), the current Other Long-Term Liabilities is $2.54 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jasper Therapeutics Business Description

Address 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
30GF Score

Get the complete analysis for JSPR

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price